Abstract
Background
Mycophenolate mofetil (MMF) is used as a steroid-sparing agent in pediatric nephrotic syndrome (NS). However, data about its long-term efficacy and safety is limited.
Methods
We report the long-term outcome of MMF therapy in 46 NS patients who remained steroid dependent (SD) despite previous treatment with levamisole and cyclophosphamide.
Results
After 1 year of MMF initiation, 32 (70 %) patients had reduced steroid requirement: 12 with decreased threshold dose and 20 were able to stop steroids. At follow-up of mean 3.56 (standard deviation + 1.76) years, 25 (54 %) children required no further alternative immunosuppression (IS), having infrequent or no relapses, of which 14 stopped MMF after a mean 2.4 (standard deviation + 0.9) years; 11 are continuing on MMF for a median of 2.25 years (range 1.33–7.75 years). One patient had a psoriasis flare, and MMF was stopped. No other patient required permanent drug withdrawal due to side effects. The outcome of patients who did not require further alternate IS was significantly better than those who did, with 56 % vs. 10.5 %, respectively, being off regular medications at last follow-up.
Conclusions
We conclude that MMF therapy is safe in the long term and allows >50 % of severe SDNS patients to avoid further toxic IS.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Tarshish P, Tobin JN, Bernstein J, Edelman CM (1997) Prognostic significance of the early course of minimal change nephritic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 8:769–776
Niaudet P (2009) Long-term outcome of children with steroid sensitive idiopathic nephrotic syndrome. Clin J Am Soc Nephrol 4:1547–1548
Niaudet P, Boyer O (2009) Idiopathic nephrotic syndrome in children: clinical aspects. In: Pediatric Nephrology, 6th edition, editors: Avner ED, Harmon W, Naiudet P, Yoshikawa N. publishers: Springer-Verlag. 28:667–702
Bagga A, Ali U, Banerjee S, Kanitkar M, Phadke KD, Senguttuvan P, Sethi S, Shah M, Indian Pediatric Nephrology Group, Indian Academy of Pediatrics (2008) Management of steroid sensitive nephrotic syndrome: revised guidelines. Indian Pediatr 45(3):203–214
van Husen M, Kemper MJ (2011) New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol 26(6):881–892
Hodson EM, Craig JC, Willis NS (2005) Evidence-based management of steroid-sensitive nephrotic syndrome. Pediatr Nephrol 20(11):1523–1530
Hodson EM, Alexander SI (2008) Evaluation and management of steroid-sensitive nephrotic syndrome. Curr Opin Pediatr 20(2):145–150
Dorresteijn EM, Kist-van Holthe JE, Levtchenko EN, Nauta J, Hop WC, van der Heijden AJ (2008) Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr Nephrol 23(11):2013–2020
Al-Akash S, Al-Makdama A (2005) Mycophenolate mofetil in children with steroid-dependent and/or frequently relapsing nephrotic syndrome. Ann Saudi Med 25(5):380–384
Hogg RJ, Fitzgibbons L, Bruick J, Bunke M, Ault B, Baqi N, Trachtman H, Swinford R (2006) Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol 1(6):1173–1178
Novak I, Frank R, Vento S, Vergara M, Gauthier B, Trachtman H (2005) Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 20(9):1265–1268
Baudouin V, Alberti C, Lapeyraque AL, Bensman A, André JL, Broux F, Cailliez M, Decramer S, Niaudet P, Deschênes G, Jacqz-Aigrain E, Loirat C (2012) Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial. Pediatr Nephrol 27(3):389–396
Gipson DS, Massengill SF, Yao L, Nagaraj S, Smoyer WE, Mahan JD, Wigfall D, Miles P, Powell L, Lin JJ, Trachtman H, Greenbaum LA (2009) Management of childhood onset nephrotic syndrome. Pediatrics 124(2):747–757
Fujinaga S, Ohtomo Y, Hirano D, Nishizaki N, Someya T, Ohtsuka Y, Kaneko K, Shimizu T (2009) Mycophenolate mofetil therapy for childhood-onset steroid dependent nephrotic syndrome after long-term cyclosporine: extended experience in a single center. Clin Nephrol 72(4):268–273
Barletta GM, Smoyer WE, Bunchman TE, Flynn JT, Kershaw DB (2009) Use of mycophenolate mofetil in steroid-dependent and resistant nephrotic syndrome. Pediatr Nephrol 18(8):833–837
Mendizábal S, Zamora I, Berbel O, Sanahuja MJ, Fuentes J, Simon J (2005) Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephritic syndrome. Pediatr Nephrol 20(7):914–919
Gellermann J, Querfeld U (2004) Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil. Pediatr Nephrol 19(1):101–104
Afzal K, Bagga A, Menon S, Hari P, Jordan SC (2007) Treatment with Mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. Pediatr Nephrol 22(12):2059–2065
Gulati A, Sinha A, Sreenivas V, Math A, Hari P, Bagga A (2011) Daily corticosteroids reduce infection-associated relapses in frequently relapsing nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 6(1):63–69
Allison AC, Eugui EM (2000) Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47(2–3):85–118
Morath C, Schwenger V, Beimler J, Mehrabi A, Schmidt J, Zeier M, Muranyi W (2006) Antifibrotic actions of mycophenolic acid. Clin Transplant 20(Suppl 17):25–29
Haffner D, Fischer DC (2009) Nephrotic syndrome and rituximab: facts and perspectives. Pediatr Nephrol 24(8):1433–1438
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Banerjee, S., Pahari, A., Sengupta, J. et al. Outcome of severe steroid-dependent nephrotic syndrome treated with mycophenolate mofetil. Pediatr Nephrol 28, 93–97 (2013). https://doi.org/10.1007/s00467-012-2278-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-012-2278-6